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Abstract29
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has generated great interest in the 30
medical and research communities yet remains an enigma given its unknown pathogenesis.  The 31
goal of this review is to summarize the various proposed hypotheses underlying BRONJ.  While a 32
role of the oral mucosa has been proposed, the bone is likely the primary tissue of interest for 33
BRONJ.  The most popular BRONJ hypothesis, manifestation of necrotic bone resulting from 34
bisphosphonate-induced remodeling suppression, is supported mostly by indirect evidence35
although recent data has shown bisphosphonates significantly reduce remodeling in the jaw.  36
Remodeling suppression would be expected, and has been shown, to allow accumulation of non-37
viable osteocytes while a more direct cytotoxic effect of bisphosphonates on osteocytes has also 38
been proposed.  Bisphosphonates have anti-angiogenic effects, leading to speculation that this 39
could contribute to the BRONJ pathogenesis.  Compromised angiogenesis would most likely be 40
involved in post-intervention healing although other aspects of the vasculature (e.g. blood flow) 41
could contribute to BRONJ.  Despite infection being present in many BRONJ patients, there is no 42
clear evidence as to whether infection is a primary or secondary event in the pathophysiology.  In 43
addition to these main factors proposed in the pathogenesis, numerous co-factors associated 44
with BRONJ (e.g. diabetes, smoking, dental extraction, concurrent medications), could interact 45
with bisphosphonates and affect remodeling, angiogenesis/blood flow, and/or infection.  As our 46
lack of knowledge concerning BRONJ pathogenesis is due to a lack of data, it is only through the 47
initiation of hypothesis-driven studies that significant progress will be made to understand this 48
serious and debilitating condition.  49
50
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53
Introduction54
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has become one of the most 55
prominent enigmas not only in the dental community, but in the field of skeletal biology as a 56
whole.  Confusion surrounding BRONJ exists for several reasons, including a lack of 57
understanding about how and why this condition manifests 1.  Since brought to light in 2003/200458
2-5, well over 400 manuscripts have been published concerning BRONJ.  Despite this large 59
volume of work there remain few data, yet many hypotheses, concerning the underlying 60
pathophysiology.  The goal of this review is to summarize some of the various proposed 61
hypotheses for the pathophysiology of BRONJ. 62
63
The starting point for BRONJ: Bone or soft tissue?64
As its name implies, BRONJ is often assumed to be primarily a bone condition.  The hallmark of 65
BRONJ is the existence of exposed bone with the majority of cases manifesting following dental 66
intervention 1.  As epithelialization is an essential step in post-intervention wound healing 6, 7, it 67
has been hypothesized that the soft tissue of the oral mucosa could play a significant role in 68
BRONJ.  Specifically, it has been proposed that bisphosphonates, which accumulate in the bone, 69
have direct toxic effects on the oral epithelium and inhibit normal healing of soft tissue lesions 70
caused either by dental intervention or some other trauma 8, 9.  The failure of soft tissue to heal 71
would result in exposure of the bone, which then becomes necrotic.  Although dental extraction is 72
a significant risk factor for BRONJ 10, the condition does occur in the absence of dental 73
intervention 1.  74
The effect of localized high concentration on the oral mucosa is most clearly illustrated by 75
the case report of stomatitis in a patient who held their bisphosphonate medication in their mouth 76
11.  However, use of bisphosphonates in gel form for treatment of periodontal lesions, although 77
not widely studied and only used short-term, likely present the oral mucosa with high local 78
concentrations and have not shown any adverse effects 12.  Beyond this, however, little is known 79
about bisphosphonates and the oral mucosa.  80
One key unknown for the hypothesis of soft-tissue toxicity is whether the oral mucosa, 81
comprised of epithelial and vascular tissue, is exposed to sufficient bisphosphonate levels in vivo 82
to disrupt its normal physiology.  Since bisphosphonates only accumulate in the bone 13, a 83
scenario would most likely have to exist in which large amounts of drug are liberated either all at 84
once, or at sufficiently high concentrations over a prolonged duration.  It has been suggested that 85
this would occur during dental intervention due to physical disruption of the bone 8, 9, although this 86
has not been assessed and would not explain the occurrence of BRONJ in the absence of dental 87
procedures.  Alternatively, sufficient concentrations of bisphosphonates in the saliva, or gingival 88
crevicular fluid could expose the oral mucosa to high levels of drug.  Whether or not the several 89
BRONJ risk factors, such as diabetes, smoking, and concurrent medications, play a role in 90
compromising the oral mucosa is also unclear.  Thus, while the hypothesis remains intriguing and 91
is worth further study, the skeleton seems most likely to serve as the central factor for initiation of 92
BRONJ.    93
94
Bone cells and BRONJ: Where to focus attention 95
The physiological effects of bisphosphonates on bone cells - osteoblasts, osteoclasts, and 96
osteocytes - have recently been expertly reviewed 14, 15.  Osteoclasts (Figure 1a) are the main 97
cellular target of bisphosphonates 16.  Specifically, through disruption of intracellular pathways,98
bisphosphonates suppress osteoclast-mediated bone remodeling.  As remodeling plays a vital 99
role in tissue renewal and bone healing, bisphosphonate-induced remodeling suppression 100
imparts significant effects on various tissue-level properties 17-22.  The effects of bisphosphonates 101
on osteocytes (Figure 1b), the most abundant of the bone cells, are less clear and more 102
controversial.  Evidence exists for both direct and indirect effects, most of which are centered 103
around the viability and integrity of these cells and their environment 20, 23-26.   Osteoblasts 104
(Figure 1c) appear to be the least affected of the bone cells. .  While systemic bone formation is 105
reduced in the presence of bisphosphonates, this is primarily an indirect consequence of 106
remodeling suppression and the coupling between resorption and formation. At the level of the 107
individual basic multicellular unit osteoblast activity appears unaffected 27, 28. Reports from small 108
animal models suggest that bisphosphonates may suppress osteoblastic bone formation directly 109
on those surface undergoing bone formation without prior resorption (i.e .formation modeling) 29, 110
although large animal models do not show a similar suppressive effect on periosteal surfaces 30-111
32.  Collectively, this evidence points towards the osteoclasts and/or osteocytes as the main cells 112
of interest for BRONJ pathogenesis.  113
114
Remodeling suppression and BRONJ: The basic premise of the most popular hypothesis115
Nearly every report and review of BRONJ points to bisphosphonate-induced remodeling 116
suppression as a likely mechanism.  The basic premise of this hypothesis is that the jaw has a 117
high remodeling rate and bisphosphonates suppress remodeling.  There is no debate about the 118
latter as this is the principal mechanism of action of the bisphosphonates 14, 15.  It is also clear that 119
remodeling, specifically within the intracortical envelope, is considerably higher in the jaw 120
compared to other skeletal sites.  As opposed to remodeling that occurs on bone surfaces, 121
intracortical (osteonal) remodeling occurs within cortical bone of humans and many large animals122
33.  In humans, intracortical remodeling rates of the jaw are 10-20 times higher than within the 123
cortex of the iliac crest 34, 35.  Animal studies support the limited human data, consistently showing 124
that remodeling rates in the jaw are significantly higher than in the long bones 36, 37.  The BRONJ 125
hypothesis thus follows the idea that since remodeling is high in the jaw, and bisphosphonates 126
suppress remodeling, this likely plays a role in the pathophysiology of BRONJ.  127
Bisphosphonate effects on intracortical bone remodeling of the mandible have only 128
recently been documented 20.  Following three years of daily treatment with doses of oral 129
alendronate that were either equivalent to the clinical dose for osteoporosis, or 5x higher, the 130
level of intracortical remodeling was histologically assessed in skeletally mature beagle dogs.  131
Consistent with previous work by others, untreated animals had mandible remodeling rates, 132
specifically within the alveolar region, that were >10-fold higher than within long bones.  Daily oral 133
alendronate significantly suppressed intracortical bone formation rate of the mandible compared134
to vehicle, mainly due to suppression in the alveolar bone region (Figure 2) 20.  These data 135
represent clear evidence of bisphosphonate-induced turnover suppression in the jaw and 136
although consistent with both components of the remodeling-suppression hypothesis for BRONJ 137
they do not establish a clear cause-effect relationship.138
The incidence of BRONJ is significantly higher in cancer patients compared to those 139
treated for osteoporosis 1 suggesting differences should exist in the degree of remodeling 140
suppression between these two populations.  Compared to treatment regimens used for 141
osteoporosis, treatment regimens in cancer patients use bisphosphonates with higher potency 142
and binding affinity (zoledronate and pamidronate) and involve both higher doses and more 143
frequent dosing schedules.  Differences in potencies and binding affinities among the 144
bisphosphonates are known to affect the degree of remodeling suppression 14, and both 145
treatment dose and duration are associated with BRONJ 10, 38-40.  Thus, it is reasonable to 146
hypothesize that cancer patients may experience a greater remodeling suppression within the 147
jaw, although such measurements have never been made even in pre-clinical models.  148
If remodeling suppression is part of the pathophysiology of BRONJ, one might expect it to 149
occur during the course of treatment with other anti-catabolic therapies.  Although no BRONJ 150
cases have been reported in patients treated with other anti-remodeling agents (hormone 151
replacement therapy, selective estrogen receptor modulators, and calcitonin), these agents 152
typically do not suppress turnover by more than 50%.  Denosumab, a monoclonal anti-RANKL 153
antibody currently in clinical trials for both osteoporosis and cancer populations, has been shown 154
to suppress remodeling an equal or greater extent than bisphosphonates 41, 42.  Although no 155
cases of BRONJ have been reported in patients treated with denosumab, increases in the 156
number of treated patients, as well as the duration of treatment, will help to answer questions 157
surrounding the role of remodeling suppression in BRONJ.158
Individuals with genetic mutations affecting osteoclast activity provide a means of 159
studying the effects of significant levels of remodeling suppression 43.  Several of these genetic 160
conditions have been reported to produce BRONJ-like symptoms 44, 45, supporting the idea of 161
remodeling-suppression in the pathophysiology.  For example, patients with inactivating 162
mutations in the chloride channel 7 gene have autosomal dominant osteopetrosis (ADO), a 163
condition in which osteoclast resorption is significantly compromised 45, 46.  Jaw osteomyelitis was 164
noted in 13% of patients with ADO, compared to a complete absence of osteomyelitis in the165
control population 46.  Interestingly, 5 of the ADO patients (8%) had draining fistulas and/or 166
obvious bony destruction resulting in visible defects in the jaw or palate, a similar clinical 167
presentation to that of BRONJ 47.  Patients with a different genetic condition, pyknodysostosis, an 168
autosomal recessive mutation in the cathepsin-K gene which inhibits osteoclast activity, have also 169
been shown to develop exposed bone in the oral cavity 48, 49.170
Perhaps the most intriguing reports supporting the remodeling suppression hypothesis of 171
BRONJ concern resolution of the condition subsequent to treatment with agents that stimulate 172
remodeling.  In three separate case reports, patients with confirmed BRONJ were treated with 173
teriparatide (recombinant human parathyroid hormone (1-34)), an FDA approved agent for 174
treating post-menopausal osteoporosis which acts through stimulation of bone remodeling 50-52.  175
While each of these cases involved numerous other interventions (including cessation of 176
bisphosphonate treatment, debridement, and anti-bacterial washes), the resolution of BRONJ 177
came only after introduction of teriparatide treatment.  178
The strongest challenge to the remodeling suppression hypothesis comes from children 179
with osteogenesis imperfecta.  These patients are routinely treated with high doses of 180
bisphosphonates and to date there have been no reports of BRONJ 53, 54.  It is unclear if or why 181
bisphosphonates differentially affect remodeling in the jaw of young and old subjects.  182
An important aspect of the remodeling suppression hypothesis is that much of the focus 183
has been on the pre-existing bone which may not be the true site of interest.  Similar to fracture 184
healing, after dental extraction the socket fills with woven bone which over time is remodeled into 185
lamellar bone 6, 7, 55.  The fracture healing literature clearly shows woven bone formation is not 186
compromised in the presence of bisphosphonates, yet remodeling of this callus is significantly 187
delayed 22, 56-58.  Thus, it may be that bone formed early during oral wound healing is not188
remodeled in a timely fashion and this in turn develops into BRONJ.  Although some investigation 189
has occurred looking at extractions in the presence of bisphosphonates 59, 60, these studies have 190
focused on the preservation of the alveolar bone structure. There exist no data to describe how 191
bisphosphonates affect bone that is formed post-extraction or how it is remodeled over time.192
The hypothesis of remodeling suppression as a factor in the pathophysiology of BRONJ 193
makes sense and is supported by some data.  Yet a key unanswered question is how the 194
suppression of remodeling, even at a site with high turnover, results in necrotic bone and why this 195
seems specific to the high doses of intravenous bisphosphonates.   196
197
Remodeling suppression and BRONJ: Focus on the osteocyte198
There exists limited histological assessment of BRONJ tissue, yet that which exists almost 199
universally notes the presence of empty lacunae – void of their resident osteocytes.  Osteocytes, 200
the most abundant bone cells, form an intricate communication network throughout the 201
mineralized matrix (Figure 3) and play a key role in skeletal physiology 61, 62.  While generally 202
considered a long-lived cell, the lifespan of the osteocyte is finite and therefore over time these 203
cells undergo natural death 63-65.  Under normal physiological conditions, loss of osteocytes and 204
the associated changes to tissue can likely be held in check by bone remodeling 64.  Yet as205
bisphosphonates suppress remodeling, regions of non-viable osteocytes would be expected to 206
accumulate.  207
Focal loss of viable bone matrix has been documented in a pre-clinical animal model. 208
Following three years of treatment with oral bisphosphonates, mandibles of beagle dogs 209
contained significant regions of non-viable bone matrix 20.  Using en bloc basic fuchsin staining 210
which fills all voids within the matrix (microdamage, Haversian canals, osteocyte lacunae and 211
canaliculi 66, 67), regions of non-viable bone matrix were identified by the absence of stain 212
suggesting the osteocyte network had filled with mineral (Figure 4).  Non-viable matrix was noted 213
in a fraction of bisphosphonate-treated animals (~30%), most often in the alveolar portion of the 214
bone, yet was not observed in any control animals 20.  Using this same basic fuchsin technique, 215
regions of matrix necrosis can be observed in pathological samples from BRONJ patients (Figure 216
5).  Previous studies on samples from patients with BRONJ, using more standard methods of 217
histological evaluation with hematoxylin and eosin staining, have also observed areas of bone 218
tissue with empty lacuna interspersed among areas of vital bone 68.  Although it remains unclear if 219
or how these areas of focal matrix necrosis play into BRONJ 69 these findings suggest the 220
osteocyte could have a central role in the pathophysiology.221
The accumulation of non-viable osteocytes in association with bisphosphonate treatment 222
could manifest through indirect or direct mechanisms.  As outlined above, osteocyte death is a 223
natural process and through suppression of remodeling it would be expected that regions with 224
non-viable cells would be more prevalent.  This accumulation would have little to do with 225
bisphosphonates, per se, but rather would be a result of suppressed remodeling.  If this 226
hypothesis is correct, it would be expected that other anti-remodeling agents, or other conditions 227
which result in remodeling suppression, would also result in an accumulation of non-viable bone, 228
and that it would be dose- or potency-dependent.  Additionally, it would be expected that regions 229
of non-viable bone would not be confined to the mandible but would be present throughout the 230
skeleton.  231
  An alternate hypothesis for the accumulation of non-viable osteocytes with 232
bisphosphonates is through a direct effect of these drugs on the osteocytes 9, 69.  It is well 233
accepted that bisphosphonates become embedded in the skeleton and therefore accumulate 234
over time 70, 71.  It has recently been demonstrated that systemically administered 235
bisphosphonates have access to, and become embedded in, the osteocyte lacunae 72.  As such, 236
it is possible that osteocytes could be exposed to high concentrations of bisphosphonates over 237
time which in turn could affect cell viability.  238
The effects of bisphosphonates on osteoblast/osteocyte viability have been 239
predominantly investigated in vitro.  Through connexin (Cx)-43 hemichannel transduction of 240
extracellular signal regulated kinases (ERKs), low concentrations of bisphosphonates have been 241
shown to suppress osteocyte apoptosis through maintenance of cellular connections 26, 73-75.  242
These results have translated well to in vivo models where bisphosphonates have also been 243
shown to suppress prednisone-induced 26 and mechanically-induced 25 osteocyte apoptosis.  244
However, the anti-apoptotic effects in vitro appear to be dose-dependent such that higher 245
concentrations increase osteocyte apoptosis 24.  This establishes a plausible scenario where 246
osteocytes are initially exposed to low levels of bisphosphonates which prolong osteocyte 247
longevity yet with continued treatment, particularly at high doses, concentrations of drug 248
accumulate near the osteocyte which results in cell death.  249
Whether these direct or indirect pathways connecting bisphosphonates to loss of 250
osteocyte viability play a role in BRONJ is unclear.  Of the two, the direct pathway is more 251
consistent with numerous clinical aspects of the condition.  BRONJ is more prominent in patients 252
treated with high-doses of intravenous pamidronate or zoledronate, as compared to those treated 253
at lower doses for osteoporosis 1.  Intravenous administration results in a higher skeletal 254
accumulation as compared to oral administration 13, while pamidronate and zoledronate have the 255
highest mineral binding affinities among all of the bisphosphonates 76, 77.  The increased risk of 256
BRONJ associated with treatment duration is also consistent with the accumulation of drug over 257
time.258
Given the central role of osteocytes in the regulation of the skeleton, understanding how 259
pharmacological agents affect their physiology is essential.  The effects of bisphosphonates on 260
osteocytes are only now beginning to be understood.  Despite indirect evidence that the loss of 261
osteocyte viability could play a role in the pathophysiology of BRONJ, the paucity of data results262
in this remaining a hypothesis.  263
  264
BRONJ and vasculature: The anti-angiogenic effects of bisphosphonates.265
Prior to the emergence of BRONJ, much of what was known concerning osteonecrosis centered 266
on two conditions which manifest due to disruptions in vasculature.  Avascular necrosis of the hip 267
occurs secondary to disruption of the vasculature 78.  Similarly, osteoradionecrosis, most 268
prominently of the jaw, occurs following radiation-induced disruption of the vasculature 68, 79, 80.  269
The existence of these conditions, and the clear role of disrupted vasculature in their 270
pathophysiology, has led to the hypothesis that the vasculature plays a key role in 271
pathophysiology of BRONJ.  272
A role of the vasculature in BRONJ has been mostly fueled by studies showing anti-273
angiogenic properties of bisphosphonates.  Indeed, bisphosphonates are emerging as a potential 274
means of suppressing angiogenesis associated with tumor growth 81, 82.  Numerous studies have 275
documented anti-angiogenic effects of bisphosphonates in vitro while a smaller number have 276
shown similar effects in vivo.  The latter include suppression of angiogenesis in subcutaneously 277
implanted tissue chambers 83, reduced testosterone-induced prostate tissue re-vascularization 278
following castration 84, and significant reductions in marrow vessel number of iliac crest biopsies 279
after six months of clodronate treatment for Paget’s disease 84.  Conversely, early in vivo studies 280
with high doses of bisphosphonates did not document altered vascular invasion near the growth281
plates 85.  There have been no systematic studies assessing the vascular pattern in BRONJ.  282
Qualitatively, the vasculature has been reported to be intact in a series of BRONJ cases 86 while 283
a separate series reported ‘vessel obliteration’ in some BRONJ specimens 68, 87.  In the dog 284
model of matrix necrosis the vasculature appears to be patent and intact even in regions devoid 285
of viable osteocytes 20. 286
Recently, two cases of exposed bone in the mandible, similar in nature to BRONJ, have 287
been reported in cancer patients treated with Bevacizumab, a recombinant human monoclonal 288
antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis 88.  289
These patients were not treated with bisphosphonates and did not undergo any dental 290
intervention.  This provides the strongest evidence to date suggesting a role of the vasculature in 291
BRONJ.292
Reduced angiogenesis within bone would actually be expected to occur with 293
bisphosphonates, due to a suppression of remodeling.  Each remodeling unit receives its 294
nutrients by a vessel 89; therefore bone remodeling and angiogenesis are intimately linked.   295
Bisphosphonate-induced reductions in remodeling should be associated with reduced 296
angiogenesis yet the reduction would be a secondary effect.  It remains unclear if this has 297
relevance to BRONJ.  298
Perhaps the most intriguing role of altered angiogenesis with bisphosphonates may be299
related to wound healing 90.  Following tooth extraction, a major precipitating event in BRONJ 10,300
the extraction site undergoes a well-defined series of healing steps which include an initial clot 301
formation, conversion of clot to granulation tissue, formation of connective tissue and pre-302
osseous tissue, and finally filling of the extraction socket with bone 7, 91-93.   Disruption of this 303
normal process at any stage, particularly the formation of the provisional matrix that occurs early 304
during treatment, could compromise the entire process 90.  Furthermore, disruption of the 305
remodeling of this extraction site by osteoclasts, which normally occurs via an accelerated rate of 306
modeling and remodeling 55, 93, may potentially play into the lack of healing that is a prominent 307
feature of BRONJ.  The sole evidence on this topic comes from an in vivo study in mice which 308
showed that bisphosphonates did not affect angiogenesis associated with endochondral 309
ossification, a process that is similar to that which occurs with skeletal wound healing 94. 310
Another aspect related to vasculature, but not as routinely discussed in the BRONJ 311
literature as angiogenesis, is potential effects of bisphosphonates on blood flow 90.  Tissue blood 312
flow is directly proportional to its metabolic activity with the bone receiving ~4-7% of total cardiac 313
output at rest 95 compared to ~17% for skeletal muscle 96.  Blood flow distribution throughout the 314
skeleton is heterogeneous and varies by a factor of ten among bones 97.  Given its high 315
remodeling rate, the mandible would be expected to have high blood flow rates.  The lone data 316
concerning mandible blood flow show values for the mandible that are similar to long bones 97, 98.  317
Importantly, however, these flow rates in the mandible are probably underestimated as the teeth 318
likely account for a significant portion of the mass, yet do not directly receive blood.  Regardless 319
of basal blood flow, it would be expected that blood flow to the mandible would be reduced with 320
bisphosphonates due to the suppression of remodeling (which would lower the metabolic 321
demand).   This reduced blood flow would lead to vascular remodeling 99 with the skeletal vessels 322
becoming smaller and thus less able to accommodate the demands for skeletal perfusion that are 323
known to exist post-extraction or with infection 100, 101.   The inability to raise blood flow in these 324
circumstances could compromise tissue viability and play a role in BRONJ.  325
326
BRONJ and Infection: It’s there but does it contribute to the pathophysiology327
Numerous bacteria have been reported in patients with BRONJ yet there is nearly a universal 328
presence of Actinomyces 68, 86, 87 102.  Actinomyces species, most commonly Actinomyces israelii,329
are the most prominent of the over 500 microflora in the oral cavity 103.  Through their formation of 330
a biofilm on the bone/tooth/mucosal surface, Actinomyces perpetuate the adherence of other 331
microflora which results in a heterogeneous population of bacteria primed for development of 332
infection 103.  Despite the presence of these bacterial conglomerates in many patients with 333
BRONJ, there is no clear evidence to address the question of whether infection is a primary or 334
secondary event in BRONJ pathophysiology.   335
One plausible mechanism through which infection could contribute to BRONJ is by 336
enhancing osteoclast-independent bone resorption.  BRONJ tissue consistently shows a 337
prevalence of scalloped bone surfaces 68, 86, 87 (Figure 5), a seemingly paradoxical property given 338
the effect of bisphosphonates on bone resorption.  Bacteria and associated fibroblast-like cells 339
have the capacity to directly resorb bone, independent of osteoclasts, by liberating various acids 340
and proteases 102, 104, 105.  As osteoclasts signal osteoblasts during normal bone remodeling 106, 341
107, resorption that occurs independent of osteoclasts would likely lack osteoblast-mediated bone 342
formation.  Whether such resorption could factor into BRONJ is unclear but seems worth 343
exploring.344
345
Other hypotheses of BRONJ 346
In addition to the hypotheses outlined above, numerous others exist mostly related to the role of 347
various co-factors in the pathophysiology of BRONJ.  Co-morbidities (e.g. diabetes 108), lifestyle 348
factors (e.g. smoking 109 and obesity 109), interventions (e.g. dental extraction 10), and concurrent349
medications (e.g. corticosteroids (110)) have all been associated with BRONJ. With all of these 350
factors, the proposed mechanism for contribution to BRONJ relates back to the main 351
mechanisms outlined above – remodeling, angiogenesis/blood flow, and infection.  As dental 352
manifestations similar to BRONJ have not been observed with any of these co-factors in the 353
absence of bisphosphonates, it suggests either these co-factors don’t play a significant role or 354
that it is the interaction between the co-factors and bisphosphonates that is the key to the 355
pathophysiology.356
357
Future Directions:  Data anyone?358
Above all else, the field of BRONJ needs data.  The amount of data, excluding those concerning 359
incidence/prevalence/risk factors, is appalling given the five years that have passed since the 360
initial descriptions of this condition.  Without undertaking hypothesis-driven studies to tease apart 361
the potential pathophysiology we simply won’t get any closer to understanding this condition.  362
Recently, the American Society for Bone and Mineral Research organized a multi-disciplinary 363
task force concerning BRONJ which put forward several questions/areas of study, ranging from 364
clinical to molecular, that the field needs to advance 1.  While this provides an excellent starting 365
point, the topics outlined are not all encompassing; other important areas related to BRONJ 366
surely exist.  The key is that we need to start generating data, without which interest in BRONJ367
within the research community will wane as the field will simply not move forward.  We are 368
dangerously close to this happening and for the sake of the patients with BRONJ we must do 369
everything we can to understand all that we can.370
371
372
Figure Legends373
374
Figure 1.  The pathophysiology of BRONJ likely involves one or more of the bone cell375
populations.  Osteoclasts (A), seen here stained with tartrate-resistant acid phosphatase, 376
function to resorb bone; suppression of their activity is the mechanism underlying the377
effectiveness of bisphosphonate treatment.  Osteocytes (B), entombed within the mineralized 378
matrix, are connected to each other and to the bone surface by an intricate cell process network 379
(seen here stained with basic fuchsin); the effect of bisphosphonates on these cells remains 380
controversial.  Osteoblasts (C), seen here as tall cuboidal cells actively forming osteoid (the thin 381
pale blue seam adjacent to the bone surface), are less active in the presence of bisphosphonates 382
although this is predominately an indirect effect of reduced bone remodeling. Scale bars = 50 µm.383
384
Figure 2.  Bisphosphonates reduce mandible bone remodeling.  Following three years of 385
daily treatment with oral alendronate (ALN), at the dose used for osteoporosis treatment (ALN 386
0.2) or a dose 5x higher (ALN1.0), intracortical bone formation rate was assessed in the mandible387
of female beagle dogs. There was a significant reduction in the overall bone formation rate of the 388
mandible with both doses of alendronate compared to age-matched animals treated with vehicle. 389
The greatest suppression of turnover was noted in the alveolar portion of the mandible with no 390
significant effect of ALN treatment on turnover suppression in the non-alveolar portion. *p < 0.05 391
versus VEH.  Adapted from J Oral Maxillofac Surg, 66(5), MR Allen and DB Burr, Mandible Matrix 392
Necrosis in Beagle Dogs After 3 Years of Daily Oral Bisphosphonate Treatment, 2008, with 393
permission from Elsevier.  394
395
Figure 3.  The osteocyte lacunar-canalicular network.  Using acid etching of plastic embedded 396
specimens, the intricate nature of the lacunar-canalicular system can be revealed.  Disruption of 397
this network could play a significant role in the pathophysiology of BRONJ.   Scale bar = 50 µm.  398
Image complements of Daniel Kubek, Indiana University School of Medicine.  399
400
Figure 4.  Mandible matrix necrosis following bisphosphonate treatment in a pre-clinical 401
model.  Following three years of daily treatment with alendronate (ALN), regions of focal matrix 402
necrosis existed in the mandibles of beagle dogs.  Using en bloc basic fuchsin staining, which 403
passively diffuses and fills all void spaces (blood vessels, lacunae, canaliculi), viable bone matrix 404
tissue can easily be identified by the presence of stain; the absence of stain indicates the lack of 405
permeability to a given region.  In this representative photomicrograph of a mandible from an 406
ALN-treated animal, the central region is noticeably void of stain and therefore considered to be 407
non-viable tissue.  Peripheral to the central region of non-viable bone matrix, tissue that is 408
sufficiently stained (and therefore considered viable) can be observed.  The upper right of the 409
photomicrograph shows the tooth, below which is the periodontal ligament (which is heavily 410
stained with fuchsin).  Scale bar = 500 µm.411
412
Figure 5.  Non-viable bone matrix in BRONJ specimens.  Using en bloc basic fuchsin staining, 413
regions of non-viable bone matrix can be observed in a pathological specimen from a patient with 414
BRONJ (courtesy of Dr. Salvatore Ruggiero).  Similar to that observed in bisphosphonate-treated 415
beagle dogs, a region void of fuchsin stain, and therefore considered non-viable, is surrounded by 416
stained (viable) tissue.  Scale bar = 100 µm.  417
418
Figure 6.  Extensive scalloped bone surfaces in BRONJ tissue.  Using high-resolution micro-419
computed tomography (Skyscan 1172, 5 µm resolution), the extent of eroded surfaces (examples 420
shown by arrows) in a sequestrum from a patient with BRONJ (courtesy of Dr. Salvatore 421
Ruggiero) can be visualized.  Such extensive erosion would be unexpected in patients treated 422
with bisphosphonates, suggesting osteoclast-independent mechanisms of bone resorption may 423
be active in BRONJ. Scale bar = 1 mm.  424
425
426
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